Fig 1: The prognostic significance and performance of SHMT2 in breast cancer patients. Kaplan-Meier analysis was performed to validate the prognostic significance of SHMT2. For protein levels of SHMT2 (ZJU set), the analysis was stratified as SHMT2-low (− and +) and SHMT2-high (++ and +++). For the mRNA levels of SHMT2 (NKI set), breast cancer patients were stratified into four subgroups based on their SHMT2 expression levels. Q0 was the 0 to the 25th percentile; Q1 was the 25th percentile to the median; Q2 was the median to the 75th percentile; and Q3 was the 75th percentile to the maximum. The Q0, Q1, Q2, and Q3 subgroups represent SHMT2 mRNA levels, from low to high. The stratification method is described in Materials and methods. (A) The protein levels of SHMT2 and OS. (B) The protein levels of SHMT2 and PFS. (C) The mRNA levels of SHMT2 and OS. (D) The mRNA levels of SHMT2 and PFS. (E) The Cox analyses for SHMT2, the 70-gene signature, wound-response gene signature, 21-gene recurrence score, and TNM stage, NKI set; *p<0.05, **p<0.01.
Fig 2: Clinical relevance of SHMT2 in breast cancer. Protein expression levels of SHMT2 and other biomarkers were determined using immunohistochemistry (IHC) staining. (A) Representative IHC images stained with SHMT2 (magnification, ×200). (B) SHMT2 protein expression levels associated with pathological tumor and lymph node stage (pT and pN stages), poor differentiation and MKI-67 in ZJU set. Here, pT is pathological tumor stage; and the number represent tumor stage. pN is pathological lymph node stage; the number indicates how many lymph nodes involved. pN>3 is >3 lymph nodes were involved. Mod, moderate differentiation; Neg, negative; Pos, positive. (C) ANOVA analysis result for SHMT2 mRNA expression levels and tumor size, pN and TNM stages, Elson grade, and intrinsic molecular subtypes of breast cancer. TNBC, basal-like breast cancer; HER2, Her2-positive, LA, luminal A; LB, luminal B; NL, normal breast-like. The p-values represent overall ANOVA analysis results.
Fig 3: Stratification analysis for prognostic performance of SHMT2 in subgroups of ER-negative and ER-positive breast cancers. For the public breast cancer microarray data, we pooled all eligible breast cancers after normalization. (A) Cox proportional hazard analysis of SHMT2 for OS in ER-negative and ER-positive breast cancer. (B) Comparison of prognostic value of SHMT2 for PFS between ER-negative and ER-positive breast cancer. (C) Kaplan-Meier analysis was used to visualize the dose-dependent relationship between SHMT2 and the OS in ER-negative breast cancer. (D) mRNA levels of SHMT2 and OS in ER-positive breast cancer. (E) Comparing the prognostic performance of SHMT2 with other factors in ER-negative breast cancers. The HR of OS for various expression levels of SHMT2, HER2, lymph node involvement, distant metastasis, Elson grade, uPA and RRM2 were determined using Cox proportional hazard analysis. LN, lymph node; Met, metastasis; *p<0.05, **p<0.01.
Fig 4: Enrichment gene set analysis for SHMT2 mRNA expression and gene signatures in breast cancers. The normalized enrichment score (ES) represents the strength of the relationship between phenotype and gene signature. The statistical significance of each signature is labeled at the side of the bar (*p<0.05, **p<0.01). Detailed information about this computational method can be obtained from ref. 30. The heat maps indicate the correlation between phenotype and expression levels of each signature gene. Columns are individual samples, and rows represent each gene. Each cell in the matrix represents the expression level of a gene in an individual sample. Red indicates a high level of expression, and green indicates a low level of expression; blue bars are invasive breast cancer signatures; purple bars are gene signatures associated with metastasis; yellow bars are mitochondria signature modules. (A) GESA analysis of SHMT2-high breast cancer. (B) GSEA results of the Wong mitochondria module. (C) Analysis results of Poola invasive breast cancer (downregulation) gene signature.
Fig 5: Stratification analysis for efficiency of chemotherapy in stage IIa breast cancer with different expression of SHMT2. In the Kaplan-Meier analysis, all participants in the NKI set were re-stratified as SHMT2-low (Q1 and Q2) or SHMT2-high (Q3 and Q4) subgroups. The HR represents the relative risk of chemotherapy (yes vs. no). Adj-HR is adjusted HR, the value of HR was adjusted by co-factors including age, hormone therapy, Elson grade and intrinsic molecular subtype. (A) Kaplan-Meier analysis of PFS for chemotherapy on SHMT2-low stage IIa breast cancer subgroup. (B) OS analysis for chemotherapy SHMT2-low stage IIa breast cancer subgroup. (C) PFS analysis for chemotherapy SHMT2-high stage IIa breast cancer subgroup. (D) OS analysis for chemotherapy SHMT2-high stage IIa breast cancer subgroup. (E) Multivariate Cox proportional hazard analysis for chemotherapy at different expression levels of SHMT2 subgroups.
Supplier Page from Abcam for Anti-SHMT2/SHMT antibody